UY33924A - Compuestos de triazolopiridina como inhibidores de cinasa pim - Google Patents

Compuestos de triazolopiridina como inhibidores de cinasa pim

Info

Publication number
UY33924A
UY33924A UY0001033924A UY33924A UY33924A UY 33924 A UY33924 A UY 33924A UY 0001033924 A UY0001033924 A UY 0001033924A UY 33924 A UY33924 A UY 33924A UY 33924 A UY33924 A UY 33924A
Authority
UY
Uruguay
Prior art keywords
compounds
triazolopiridine
cimasa
pim
pim inhibitors
Prior art date
Application number
UY0001033924A
Other languages
English (en)
Spanish (es)
Inventor
Eli M Wallace
Michael Lyon
Robert Kirk Delisle
James F Blake
James M Graham
John E Robinson
Lisa A De Meese
Yvan Le Heurou
Wang Bin
Xu Rui
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of UY33924A publication Critical patent/UY33924A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001033924A 2011-02-25 2012-02-24 Compuestos de triazolopiridina como inhibidores de cinasa pim UY33924A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161446902P 2011-02-25 2011-02-25

Publications (1)

Publication Number Publication Date
UY33924A true UY33924A (es) 2013-09-30

Family

ID=46000320

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033924A UY33924A (es) 2011-02-25 2012-02-24 Compuestos de triazolopiridina como inhibidores de cinasa pim

Country Status (32)

Country Link
US (1) US8889704B2 (enExample)
EP (1) EP2678329B1 (enExample)
JP (2) JP6039585B2 (enExample)
KR (1) KR101940338B1 (enExample)
CN (1) CN103492377B (enExample)
AR (1) AR085489A1 (enExample)
AU (1) AU2012254082B2 (enExample)
BR (1) BR112013021675A2 (enExample)
CA (1) CA2828269C (enExample)
CL (1) CL2013002446A1 (enExample)
CO (1) CO6771441A2 (enExample)
CR (1) CR20130460A (enExample)
CY (1) CY1117197T1 (enExample)
DK (1) DK2678329T3 (enExample)
ES (1) ES2563152T3 (enExample)
HR (1) HRP20160134T1 (enExample)
HU (1) HUE027675T2 (enExample)
IL (1) IL228108A (enExample)
ME (1) ME02365B (enExample)
MX (1) MX339899B (enExample)
PH (1) PH12013501754A1 (enExample)
PL (1) PL2678329T3 (enExample)
RS (1) RS54586B1 (enExample)
RU (1) RU2598846C2 (enExample)
SG (1) SG192944A1 (enExample)
SI (1) SI2678329T1 (enExample)
SM (1) SMT201600052B (enExample)
TW (1) TWI529170B (enExample)
UA (1) UA111075C2 (enExample)
UY (1) UY33924A (enExample)
WO (1) WO2012154274A1 (enExample)
ZA (1) ZA201306997B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
RU2014145806A (ru) * 2012-04-25 2016-06-10 Ф. Хоффманн-Ля Рош Аг Способы производства (3,4-дихлорфенил)-((s)-3-пропил-пирролидин-3-ил)-метанонгидрохлорида
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3464270B1 (en) * 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP2021521170A (ja) 2018-04-13 2021-08-26 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
US20220363667A1 (en) 2018-07-17 2022-11-17 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
KR20260008165A (ko) 2019-02-12 2026-01-15 스미토모 파마 아메리카, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
EP3929185A4 (en) * 2019-02-19 2023-02-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NITROGEN CONDENSED CYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF
AU2020250468A1 (en) 2019-03-29 2021-11-04 Kinki University Use of T-type calcium channel blocker for treating pruritus
CN111171023B (zh) * 2020-01-10 2021-12-21 中国药科大学 一种具有Pim1抑制活性的化合物及其制备方法与医药用途
CN120302975A (zh) 2022-10-31 2025-07-11 住友制药美国公司 治疗骨髓增生性肿瘤的pim1抑制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388593A1 (en) 1999-11-12 2001-05-17 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
HUP0303415A2 (hu) 2001-03-09 2004-01-28 Pfizer Products Inc. Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
US7227006B2 (en) 2002-01-19 2007-06-05 Sanofi-Aventis Deutschland Gmbh PIM-3 kinase as a target for type 2 diabetes mellitus
WO2004058769A2 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
WO2005028624A2 (en) 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
BRPI0514391A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos de triazolopiridina para o tratamento de inflamação
EP1828184B1 (en) 2004-12-01 2009-09-16 Merck Serono SA [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
WO2007044724A2 (en) 2005-10-06 2007-04-19 Exelixis, Inc. Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
EP1978966A4 (en) 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
EP2029605A1 (en) 2006-06-06 2009-03-04 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008108958A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Benzimidazole derivatives and methods of use thereof
JP2010522765A (ja) * 2007-03-28 2010-07-08 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物
NZ580327A (en) * 2007-04-03 2012-02-24 Array Biopharma Inc IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
WO2010039825A2 (en) * 2008-10-01 2010-04-08 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
AU2010229142A1 (en) * 2009-03-23 2011-10-13 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
TW201245193A (en) 2012-11-16
CO6771441A2 (es) 2013-10-15
JP2016106118A (ja) 2016-06-16
CN103492377A (zh) 2014-01-01
EP2678329B1 (en) 2015-11-18
HUE027675T2 (en) 2016-11-28
HRP20160134T1 (hr) 2016-04-08
TWI529170B (zh) 2016-04-11
CL2013002446A1 (es) 2014-04-11
RU2598846C2 (ru) 2016-09-27
JP2014509322A (ja) 2014-04-17
EP2678329A1 (en) 2014-01-01
US20140005213A1 (en) 2014-01-02
IL228108A (en) 2017-07-31
ME02365B (me) 2016-06-20
SMT201600052B (it) 2016-04-29
ZA201306997B (en) 2015-05-27
CN103492377B (zh) 2016-04-20
UA111075C2 (uk) 2016-03-25
US8889704B2 (en) 2014-11-18
WO2012154274A1 (en) 2012-11-15
IL228108A0 (en) 2013-09-30
CY1117197T1 (el) 2017-04-05
DK2678329T3 (da) 2016-02-22
AR085489A1 (es) 2013-10-09
KR101940338B1 (ko) 2019-01-18
HK1190714A1 (zh) 2014-07-11
SI2678329T1 (sl) 2016-05-31
ES2563152T3 (es) 2016-03-11
PL2678329T3 (pl) 2016-06-30
SG192944A1 (en) 2013-09-30
CA2828269C (en) 2019-01-15
CA2828269A1 (en) 2012-11-15
AU2012254082A1 (en) 2013-09-26
RS54586B1 (sr) 2016-08-31
JP6039585B2 (ja) 2016-12-07
BR112013021675A2 (pt) 2016-11-01
AU2012254082B2 (en) 2016-12-08
KR20140021577A (ko) 2014-02-20
MX2013009820A (es) 2014-09-01
CR20130460A (es) 2013-10-16
NZ615300A (en) 2014-12-24
MX339899B (es) 2016-06-16
RU2013143292A (ru) 2015-04-10
PH12013501754A1 (en) 2013-10-14

Similar Documents

Publication Publication Date Title
UY33924A (es) Compuestos de triazolopiridina como inhibidores de cinasa pim
ECSP22091792A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos
MX2019007080A (es) Compuestos de benzimidazol como inhibidores de c-kit.
ECSP18012103A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CU20120101A7 (es) Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
NI201300074A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos.
GT201400187A (es) Derivados macrocíclicos para el tratamiento de enfermedades
CU24097B1 (es) Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas
UY33883A (es) Novedosos derivados heterocíclicos
CL2016000150A1 (es) Compuestos y composiciones como inhibidores de la mek
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CL2012002229A1 (es) Compuestos derivados de macrociclos inhibidores del factor de coagulacion xia; utiles en el tratmiento de enfermedades tromboembolicas.
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
PA8841901A1 (es) Compuestos orgánicos
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
MX2019006893A (es) Inhibidores heterociclicos de mct4.
CR20130610A (es) Método de tratamiento de la fiebre dengue
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CR20150148A (es) Azaindolinas
PE20150674A1 (es) Azaheterociclos como inhibidores de bir2 y/o bir3
CR20120166A (es) Composiciones y productos antimicrobianos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211216